Elevance Health
✦ StockVane Quant Insights how this is computed
- Twelve-month momentum in the top 28% of the universe, above its 200-day average.
- Signal has read BUY for 1 day.
- Its last 4 Buy calls have averaged close to flat (-2%) three months out - no strong edge on this name specifically.
- Recent price momentum is +21.6% on average (3-month/1-year).
- Main-fund capital flow has been a net outflow over the last 45 sessions.
- Short interest has risen to 2.4% of float.
- Analyst tilt is Buy.
- Price is below its 20-day average and above its 60-day average.
- The 20-day average is above the 60-day average, a short-term uptrend.
Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.
Factor grades
Ranked against 2852 U.S. stocks StockVane covers.
Valuation B
How expensive the stock is versus earnings, sales and its own 5-year history.
| P/E (TTM) | 18.9x | Better than 51% |
| Forward P/E | 17.4x | Better than 48% |
| Price / Sales | 0.5x | Better than 92% |
| P/E vs own 5-yr range | 75th pctl | Better than 34% |
Growth C
How fast revenue, profit and free cash flow are compounding.
| Revenue CAGR (3Y) | 8.3% | Better than 59% |
| Net income CAGR (3Y) | -1.3% | Better than 39% |
| Free cash flow CAGR (3Y) | -24.1% | Better than 15% |
Profitability B-
How much profit the business keeps from each dollar of sales and capital.
| Net margin | 2.8% | Better than 36% |
| Return on equity | 13.3% | Better than 63% |
Momentum A
Recent price strength, skipping the latest month to avoid short-term noise.
| 3-month return | 18.4% | Better than 85% |
| 6-month return | 30.2% | Better than 85% |
| 12-month return (ex latest month) | 17.4% | Better than 57% |
| Distance below 52-week high | 1.2% | Better than 95% |
Financial Health C
Balance-sheet strength: leverage, liquidity and interest coverage.
| Debt to assets | 26.4% | Better than 47% |
| Interest coverage | 5.8x | Better than 60% |
| Free cash flow / net income | 56.1% | Better than 16% |
Analyst View C-
What the Street thinks: share of Buy ratings and upside to the average target.
| Analysts rating Buy | 62.5% | Better than 39% |
| Upside to average target | 1.1% | Better than 11% |
Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector, so capital-light software tends to grade lower there than utilities. Recomputed every 6 hours from our market data. Not investment advice, and not tailored to your financial situation, goals, or risk tolerance.
Price chart
Anonymous reader poll. Unscientific, not investment advice.
Performance
Key statistics
Price & volume
- Prev close
- 413.60
- Open
- 412.82
- Day range
- 411.46 - 420.00
- Avg price
- 414.00
- Volume
- 917.42K
- Turnover
- 379.81M
- Turnover ratei
- 0.43%
- Volume ratioi
- 0.63
- Amplitudei
- 2.07%
- 52-week rangei
- 270.87 - 450.69
Valuation
- P/Ei
- 16.41
- P/E (TTM)i
- 17.57
- P/Bi
- 2.00
- EPSi
- 25.21
- Book value / shi
- 206.80
- Net profit
- 5.45B
- Net assets
- 44.68B
Share structure
- Market cap
- 89.39B
- Float capi
- 89.19B
- Shares out
- 216.06M
- Float sharesi
- 215.57M
Dividend & listing
- Div yield (TTM)i
- 1.66%
- Dividend (TTM)
- 6.87
- Listing date
- 1970-01-01
8.2% below the 52-week high
Trading activity
Net capital flow main funds, last 45 sessions
-57.56M net over the window
Short interest
- Shares short
- 5.14M
- % of floati
- 2.37%
- Days to coveri
- 4.00
- As of
- 2026-10-15
Frequently asked questions
What is the current stock price of Elevance Health (ELV)?
Elevance Health last traded at 413.75. The quote on this page refreshes every few seconds while US markets are open.
What is Elevance Health's market cap?
About 89.39B.
What is the P/E ratio of Elevance Health?
The trailing twelve-month P/E is 17.57, above its own 5-year average of 17.17 — in the middle of its historical range (54.66% percentile). See the Valuation tab for the full history.
Does Elevance Health pay a dividend?
Yes. The trailing dividend yield is 1.66%. The 2025 payout was up 4.9% from 2024. See the Dividends tab for the full payment history.
Is Elevance Health a buy according to analysts?
The consensus of 13 analysts is a Buy rating, with an average 12-month price target of 481.75, which implies 16.4% upside from the current price. This is not investment advice.
What is Elevance Health's StockVane Quant Rating?
The StockVane Momentum strategy currently rates Elevance Health a B (Buy). Twelve-month momentum in the top 28% of the universe, above its 200-day average. Not investment advice.
Quote time 2026-11-04 06:49:10 · For reference only, not investment advice and not tailored to your situation.
Elevance Health discussion 0 comments